Statistical consideration for clinical biomarker research in bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 4, 2010, Pages 389-400

  Shariat, Shahrokh F ^a,b   Lotan, Yair ^c   Vickers, Andrew ^a   Karakiewicz, Pierre I ^d   Schmitz Dräger, Bernd J ^e   Goebell, Peter J ^f   Malats, Nuria ^g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f Euromed Clinic   (Germany)

^g Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Biomarker; Bladder cancer; Decision analysis; Diagnosis; Nomogram; Prognosis; Statistical analysis; statistics; Treatment

Indexed keywords

BIOLOGICAL MARKER; CYCLIN E; KI 67 ANTIGEN; NUCLEAR MATRIX PROTEIN 22; PROTEIN P21; PROTEIN P27; PROTEIN P53;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SCREENING; EXTERNAL VALIDITY; HUMAN; INFORMATION; MEDICAL RESEARCH; METHODOLOGY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; VALIDATION STUDY; STATISTICS AND NUMERICAL DATA; URINARY BLADDER NEOPLASMS;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; HUMANS; URINARY BLADDER NEOPLASMS; VALIDATION STUDIES AS TOPIC;

EID: 77953817519     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.02.011     Document Type: Review

References (73)

1. Egawa S., and Kuruma H. Search for biomarkers of aggressiveness in bladder cancer. Eur Urol 50 (2006) 20-22
2. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
3. van Gils M.P., Stenman U.H., Schalken J.A., et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 48 (2005) 1031-1041
4. Shariat S.F., Kattan M.W., Vickers A.J., et al. Critical review of prostate cancer predictive tools. Future Oncol 5 (2009) 1555-1584
5. Vickers A.J., and Lilja H. Cutpoints in clinical chemistry: Time for fundamental reassessment. Clin Chem 55 (2009) 15-17
6. Steyerberg E.W., Vickers A.J., Cook N.R., et al. Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology 21 (2010) 128-138
7. Schmitz-Drager B.J., Fradet Y., and Grossman H.B. Bladder cancer markers in patient management: The current perspective. World J Urol 26 (2008) 1-3
8. Ilyin S.E., Belkowski S.M., and Plata-Salaman C.R. Biomarker discovery and validation: Technologies and integrative approaches. Trends Biotechnol 22 (2004) 411-416
9. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
10. Svatek R.S., Lotan Y., Karakiewizc P.I., et al. Screening for bladder cancer using urine-based tumor markers. Minerva Urol Nefrol 60 (2008) 247-253
11. Shariat S.F., Zippe C., Ludecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma of the bladder. J Urol 173 (2005) 1518-1525
12. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816
13. Herman M.P., Svatek R.S., Lotan Y., et al. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol 60 (2008) 217-235
14. Goebell P.J., Groshen S., Schmitz-Drager B.J., et al. The International Bladder Cancer Bank: Proposal for a new study concept. Urol Oncol 22 (2004) 277-284
15. Huang H.Y., Shariat S.F., Sun T.T., et al. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome. Hum Pathol 38 (2007) 1703-1713
16. Schnitt S.J. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 30 (2001) 22-26
17. Shariat S.F., Karam J.A., Walz J., et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14 (2008) 3785-3791
18. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
19. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112 (2008) 315-325
20. Karam J.A., Lotan Y., Karakiewicz P.I., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8 (2007) 128-136
21. Andre F., and Pusztai L. Molecular classification of breast cancer: Implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3 (2006) 621-632
22. Grossman H.B. Are biomarkers for bladder cancer beneficial?. J Urol 183 (2010) 11-12
23. Bensalah K., Montorsi F., and Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 52 (2007) 1601-1609
24. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6 (2005) 678-686
25. Check E. Proteomics and cancer: Running before we can walk?. Nature 429 (2004) 496-497
26. Diamandis E.P. Proteomic patterns to identify ovarian cancer: 3 Years on. Expert Rev Mol Diagn 4 (2004) 575-577
27. Dalbagni G., Parekh D.J., Ben-Porat L., et al. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 99 (2007) 281-285
28. Svatek R.S., Jeldres C., Karakiewicz P.I., et al. Pretreatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69 (2009) 886-894
29. Bensalah K., Lotan Y., Karam J.A., et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11 (2008) 112-120
30. Verma M., and Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent results. Cancer Res 163 (2003) 72-84 Discussion 264-6
31. Winget M.D., Baron J.A., Spitz M.R., et al. Development of common data elements: The experience of and recommendations from the early detection research network. Int J Med Inform 70 (2003) 41-48
32. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 6 Suppl 1 (2005) 35-63
33. Goebell P.J., Groshen S.L., and Schmitz-Drager B.J. Guidelines for development of diagnostic markers in bladder cancer. World J Urol 26 (2008) 5-11
34. Shariat S.F., Canto E.I., Kattan M.W., et al. Beyond prostate-specific antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6 (2004) 58-72
35. Mandrekar S.J., and Sargent D.J. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27 (2009) 4027-4034
36. Mandrekar S.J., and Sargent D.J. Clinical trial designs for predictive biomarker validation: One size does not fit all. J Biopharm Stat 19 (2009) 530-542
37. Shariat S.F., and Karakiewicz P.I. Perspectives on prostate cancer biomarkers. Eur Urol 54 (2008) 8-10
38. Shariat S.F., Karakiewicz P.I., Roehrborn C.G., et al. An updated catalog of prostate cancer predictive tools. Cancer 113 (2008) 3075-3099
39. Shariat S.F., Karam J.A., Margulis V., et al. New blood-based biomarkers for the diagnosis, staging, and prognosis of prostate cancer. BJU Int 101 (2008) 675-683
40. Steyerberg E.W., Harrell Jr. F.E., Borsboom G.J., et al. Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54 (2001) 774-781
41. Kattan M.W. Nomograms introduction. Semin Urol Oncol 20 (2002) 79-81
42. Efron B., and Tibshirani R.J. An introduction to the bootstrap (1993), Chapman and Hall/CRC, Boca Raton, (FL)
43. Kattan M.W. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 170 6 Pt 2 (2003) S6-S9 Discussion S10
44. Steyerberg E.W., Bleeker S.E., Moll H.A., et al. Internal and external validation of predictive models: A simulation study of bias and precision in small samples. J Clin Epidemiol 56 (2003) 441-447
45. Steyerberg E.W., Harrell Jr. F.E., and Goodman P.H. Neural networks, logistic regression, and calibration. Med Decis Making 18 (1998) 349-350
46. Margulis V., Shariat S.F., Ashfaq R., et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12 (2006) 7369-7373
47. Margulis V., Lotan Y., Karakiewicz P.I., et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 101 (2009) 114-119
48. Lotan Y. Role of biomarkers to predict outcomes and response to therapy. Urol Oncol 28 (2010) 97-101
49. Vickers A.J., and Elkin E.B. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 26 (2006) 565-574
50. Vickers A.J., Cronin A.M., Elkin E.B., et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Making 8 (2008) 53-70
51. Vickers A.J. Decision-analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat 62 (2008) 314-320
52. Elkin E.B., Vickers A.J., and Kattan M.W. Primer: Using decision-analysis to improve clinical decision making in urology. Nat Clin Pract Urol 3 (2006) 439-448
53. Shariat S.F., Casella R., Wians Jr. F.H., et al. Risk stratification for bladder tumor recurrence, stage, and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45 (2004) 304-313 author reply 313
54. Elstein A.S. Heuristics and biases: Selected errors in clinical reasoning. Acad Med 74 (1999) 791-794
55. Vlaev I., and Chater N. Game relativity: How context influences strategic decision making. J Exp Psychol Learn Mem Cogn 32 (2006) 131-149
56. Hogarth R.M., and Karelaia N. Heuristic and linear models of judgment: Matching rules and environments. Psychol Rev 114 (2007) 733-758
57. Ross P.L., Gerigk C., Gonen M., et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 20 (2002) 82-88
58. Ross P.L., Scardino P.T., and Kattan M.W. A catalog of prostate cancer nomograms. J Urol 165 (2001) 1562-1568
59. Specht M.C., Kattan M.W., Gonen M., et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: Clinicians vs. nomogram. Ann Surg Oncol 12 (2005) 654-659
60. Walz J., Gallina A., Perrotte P., et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 100 (2007) 1254-1258
61. Karakiewicz P.I., Shariat S.F., Palapattu G.S., et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176 4 Pt 1 (2006) 1354-1361 Discussion 1361-2.
62. Karakiewicz P.I., Shariat S.F., Palapattu G.S., et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 50 (2006) 1254-1260 Discussion 1261-2
63. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12 (2006) 6663-6676
64. Shariat S.F., Karakiewicz P.I., Suardi N., et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res 14 (2008) 4400-4407
65. Shariat S.F., Margulis V., Lotan Y., et al. Nomograms for bladder cancer. Eur Urol 54 (2008) 41-53
66. Lerner S.P., Bochner B., and Kibel A.S. The use and abuse of data: Nomograms and talking to patients about clinical medicine. Urol Oncol 25 (2007) 333-337
67. Begg C.B., Cramer L.D., Venkatraman E.S., et al. Comparing tumor staging and grading systems: A case study and a review of the issues, using thymoma as a model. Stat Med 19 (2000) 1997-2014
68. Vickers A.J., Jang K., Sargent D., et al. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 112 (2008) 1862-1868
69. Vickers A.J., Kattan M.W., and Daniel S. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials 8 (2007) 14-25
70. Vickers A.J., Cronin A.M., Kattan M.W., et al. Clinical benefits of a multivariate prediction model for bladder cancer: A decision analytic approach. Cancer 115 (2009) 5460-5469
71. Bochner B.H., Kattan M.W., and Vora K.C. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24 (2006) 3967-3972
72. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 (2005) 1180-1184
73. Hayes D.F., Bast R.C., Desch C.E., et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466